A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion - PRIORITY

Talecris Biotherapeutics, Inc0 个研究点目标入组 188 人开始时间: 2008年1月14日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Talecris Biotherapeutics, Inc
入组人数: 188

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Age = 18 years.
•2. Women of childbearing potential must use adequate contraception for the duration of
•the study and must have a negative pregnancy test prior to study entry.
•3. Unilateral limb ischemia: symptomatic, SVS acute ischemic categories I and IIa.
•4. Onset of symptoms less or equal to 14 days.
•5. Thrombosed (non-embolic) infrainguinal graft (synthetic, autologous, or single outflow composite) or infrainguinal native artery.For native arteries, only occlusions of = 10 cm in length are eligible.
•6. Diagnosis of occlusive thrombus in the graft or artery by arteriography after
•Informed Consent is obtained.
•7. Ability to traverse the thrombus with a guidewire.
•8. Signed Informed Consent prior to study entry.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Clinical evidence of significant disease that may interfere with the patient
•successfully completing the trial.
•2. Women who are pregnant or lactating, or first 10 days post-partum.
•3. Any medical or social condition which the investigator feels wil prohibit the subject from completing the trial
•4. Cardiopulmonary resuscitation in the last 10 days.
•5. Previous systemic or anaphylactoid allergy to contrast agent, streptokinase, or blood products.
•6. Previous hemorrhagic stroke at any time.
•7. Thrombotic or embolic stroke or cerebrovascular events (including transient
•ischemic attack (TIA)) within one year.
•8. Intracranial or spinal neuro-surgery or severe intracranial trauma in the last 3
•9. Major surgery, organ biopsy, or major trauma within the last 10 days.
•10. Lumbar puncture or non-compressible arterial puncture in the last 10 days.
•11. Intra-ocular surgery within the last 10 days.
•12. Active gastrointestinal or organ bleeding. Minor bleeding such as normal menses,
•cystitis, or minor hemorrhoidal bleeding are not exclusions.
•13. Uncontrolled arterial hypertension, defined as a systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg.
•14. Known intracranial neoplasm, aneurysm, or arterio-venous malformation.
•15. Current bleeding diathesis.
•16. Platelet count < 75 x 10 exp 9 P/L.
•17. Graft infection.
•18. Occlusion of a new synthetic or autologous graft within 6 months of placement. A
•sequential composite graft with dual outflows to correct multiple occlusions is also ineligible.
•19. Medically unable to tolerate open vascular procedure.
•20. Known prothombotic state, e.g. anti-cardiolipin antibody, HIV-associated peripheral vascular disease.
•21. Known contraindication to heparin (e.g. history of heparin-induced thrombocytopenia.)
•22. Hemoglobin < 10.0 g/dL (low hemoglobin at screening in the absence of active
•bleeding may corrected by transfusion).
•23. Impaired renal function or renal disease that constitutes a contraindication to contrast angiography., including a screen/baseline creatinine of >2.0 mg/dL or subjects on renal dialysis
•24. Previous treatment with Plasmin.
•25. Treatment with full dose plasminogen activator (e.g., streptokinase (e.g., Streptase®, Kabikinase®), anistreplase (Eminase®), alteplase (e.g., Activase®), reteplase (e.g., Retavase®), tenecteplase (TNKase™), UK (Abbokinase®)) within the last 48 hours.
•26.Treatment with a glycoprotein IIb/IIIa class of platelet inhibitor within the past 5 days, for example, abciximab (ReoPro®), eptifibatide (Integrilin®) or tirofiban (Aggrastat®).
•27.Treatment with warfarin (Coumadin®) and with an INR of >1.7 (elevated INR at screening may be corrected prior to study enrollment.)
•28. Participation in another clinical trial within 30 days prior to entry (imaging studies
•without investigative treatment are permitted), or concomitant participation in
•another trial or study.
•29. Mentally challenged adult subjects who cannot give independent informed consent.

研究者

发起方

Talecris Biotherapeutics, Inc

相似试验

进行中（未招募）

1 期

A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion - PRIORITYAcute Lower Extremity Native Artery or Bypass Graft OcclusionMedDRA version: 8.1Level: LLTClassification code 10043628Term: Thrombosis NOS

EUCTR2006-002447-81-BGTalecris Biotherapeutics, Inc242

进行中（未招募）

1 期

A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion - PRIORITYAcute Lower Extremity Native Artery or Bypass Graft OcclusionMedDRA version: 8.1 Level: LLT Classification code 10043628 Term: Thrombosis NOS

EUCTR2006-002447-81-GBTalecris Biotherapeutics, Inc188

进行中（未招募）

不适用

EUCTR2006-002447-81-CZTalecris Biotherapeutics, Inc188

进行中（未招募）

不适用

EUCTR2006-002447-81-DETalecris Biotherapeutics, Inc188

进行中（未招募）

1 期

A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancerExtensive Stage Disease Small Cell Lung Cancer (ED SCLC)MedDRA version: 17.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-001764-35-ESAbbVie Deutschland GmbH & Co. KG75